TBPH
Theravance Biopharma Inc
$17.03
+0.00
(+0.00%)
Mkt Cap
882.64M
Volume
10,016,289
52W Range
13.08-21.03
Sector
Healthcare
Beta
0.17
EPS (TTM)
1.06 USD
P/E Ratio
16.01
Revenue (TTM)
104.31M USD
Rev Growth (5Y)
+8.4%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$60.83
Undervalued
strong signal
72.0% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 107.46M | 64.38M | 57.42M | 51.35M | 55.31M | 71.86M | 73.41M | 60.37M | 15.39M | 48.65M | 42.13M | 11.69M |
| Net Income | 105.89M | (56.42M) | (55.19M) | 872.13M | (199.43M) | (278.02M) | (236.46M) | (215.52M) | (285.40M) | (190.67M) | (182.22M) | (237.04M) |
| EPS | 2.10 | -1.15 | -1.00 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 |
| Free Cash Flow | 238.50M | (11.87M) | (29.48M) | (187.56M) | (211.26M) | (257.02M) | (241.37M) | (120.11M) | (203.46M) | (101.12M) | (171.50M) | (178.26M) |
| FCF / Share | 4.74 | -0.24 | -0.53 | -2.55 | -3.04 | -4.12 | -4.34 | -2.23 | -3.89 | -2.26 | -5.02 | -5.61 |
| Operating CF | 238.54M | (11.54M) | (27.00M) | (186.99M) | (207.86M) | (250.40M) | (238.20M) | (112.87M) | (201.05M) | (98.99M) | (168.86M) | (175.16M) |
| Total Assets | 485.57M | 354.16M | 382.00M | 607.40M | 374.82M | 469.06M | 408.83M | 560.24M | 441.40M | 639.25M | 300.12M | 337.77M |
| Total Debt | 75.50M | 49.82M | 49.16M | 52.16M | 669.52M | 676.26M | 510.53M | 454.35M | 223.75M | 222.68M | 0 | 0 |
| Cash & Equiv | 167.81M | 37.80M | 39.55M | 298.17M | 89.96M | 81.47M | 58.06M | 378.02M | 88.98M | 344.71M | 112.71M | 89.22M |
| Book Value | 296.72M | 175.54M | 213.00M | 441.80M | (338.57M) | (303.75M) | (223.84M) | (51.59M) | 115.18M | 350.23M | 243.06M | 289.79M |
| Return on Equity | 0.36 | -0.32 | -0.26 | 1.97 | N/A | N/A | N/A | N/A | -2.48 | -0.54 | -0.75 | -0.82 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.73M | 17.70M | 45.89M | 19.99M | 26.20M | 15.39M | 18.75M | 16.87M | 14.26M | 14.50M | 17.57M | 15.69M |
| Net Income | (5.90M) | (4.93M) | 61.02M | 3.62M | 54.84M | (13.58M) | (15.53M) | (12.70M) | (16.53M) | (11.66M) | (8.51M) | (8.95M) |
| EPS | -0.11 | -0.10 | 1.20 | 0.07 | 1.09 | -0.27 | -0.31 | -0.26 | -0.34 | -0.24 | -0.17 | -0.17 |
| Free Cash Flow | (8.88M) | 73.28M | (6.07M) | (6.51M) | 208.04M | 43.04M | (1.09M) | (5.21M) | (4.45M) | (1.11M) | (1.53M) | (2.51M) |
| FCF / Share | -0.17 | 1.43 | -0.12 | -0.13 | 4.15 | 0.87 | -0.02 | -0.11 | -0.09 | -0.02 | -0.03 | -0.05 |
| Operating CF | (8.88M) | 73.28M | (6.06M) | (6.51M) | 208.07M | 43.04M | (902,000) | (5.20M) | (4.42M) | (1.02M) | (854,000) | (2.49M) |
| Total Assets | 469.77M | 472.31M | 485.57M | 415.46M | 426.04M | 343.58M | 354.16M | 356.11M | 362.03M | 371.31M | 382.00M | 413.59M |
| Total Debt | 38.57M | 73.30M | 75.50M | 44.59M | 46.46M | 48.16M | 49.82M | 44.98M | 46.66M | 47.90M | 49.16M | 50.83M |
| Cash & Equiv | 219.77M | 288.10M | 167.81M | 174.77M | 281.93M | 110.61M | 37.80M | 23.38M | 46.34M | 53.84M | 39.55M | 71.69M |
| Book Value | 289.70M | 290.59M | 296.72M | 232.68M | 224.85M | 165.98M | 175.54M | 185.65M | 193.69M | 204.87M | 213.00M | 246.13M |
| Return on Equity | -0.02 | -0.02 | 0.21 | 0.02 | 0.24 | -0.08 | -0.09 | -0.07 | -0.09 | -0.06 | -0.04 | -0.04 |
TBPH News
CASI Pharmaceuticals (NASDAQ:CASI) & Theravance Biopharma (NASDAQ:TBPH) Financial Analysis
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
Theravance Biopharma (NASDAQ:TBPH) versus vTv Therapeutics (NASDAQ:VTVT) Head-To-Head Contrast
Theravance Biopharma (NASDAQ:TBPH) Sees Unusually-High Trading Volume – What’s Next?
Insider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells $226,737.42 in Stock
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
Empowered Funds LLC Purchases Shares of 55,463 Theravance Biopharma, Inc. $TBPH
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders